|
| Wednesday, April 22, 2026 |
|
|
Everest Medicines Announces Positive First-in-Human Data for Personalized mRNA Cancer Vaccine EVM16 at AACR 2026 |
| Everest Medicines announced that the first-in-human (FIH) clinical trial data of EVM16, a proprietary personalized mRNA cancer vaccine, were presented at the 2026 American Association for Cancer Research 'Annual Meeting (AACR 2026). more info >> |
|
|
雲頂新耀mRNA個性化腫瘤治療性疫苗EVM16於AACR 2026公佈首次人體數據積極 展現良好安全性、較強免疫原性與初步療效 |
| 雲頂新耀宣佈在2026年美國癌症研究協會（AACR）年會上公佈其自主研發的mRNA個性化腫瘤治療性疫苗EVM16單藥治療及聯合PD-1抑制劑（替雷利珠單抗）治療晚期實體瘤的首次人體臨床試驗（FIH）數據。結果顯示出良好的安全性和耐受性、顯著的免疫原性及積極的初步療效信號，支持進一步臨床開發的推進 more info >> |
|
|
云顶新耀mRNA个性化肿瘤治疗性疫苗EVM16于AACR 2026公布首次人体数据积极 展现良好安全性、较强免疫原性与初步疗效 |
| 云顶新耀宣布在2026年美国癌症研究协会（AACR）年会上公布其自主研发的mRNA个性化肿瘤治疗性疫苗EVM16单药治疗及联合PD-1抑制剂（替雷利珠单抗）治疗晚期实体瘤的首次人体临床试验（FIH）数据。 more info >> |
|
| Monday, March 23, 2026 |
|
|
Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint |
| Everest Medicines today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited (CORXEL). more info >> |
|
|
雲頂新耀達成艾曲帕米鼻噴霧劑資產收購協議 強化心血管領域產品佈局 |
| 雲頂新耀宣佈與箕星藥業香港有限公司（以下簡稱「箕星藥業」）達成資產收購協議 (The Asset Purchase Agreement)，獲得艾曲帕米（Etripamil）鼻噴霧劑（擬定中文商品名：星必妥(R)）在大中華區的開發、商業化及產品地產化權益。 more info >> |
|
|
云顶新耀达成艾曲帕米鼻喷雾剂资产收购协议 强化心血管领域产品布局 |
| 云顶新耀宣布与箕星药业香港有限公司（以下简称"箕星药业"）达成资产收购协议 (The Asset Purchase Agreement)，获得艾曲帕米（Etripamil）鼻喷雾剂（拟定中文商品名：星必妥(R)）在大中华区的开发、商业化及产品地产化权益。 more info >> |
|
| Wednesday, March 11, 2026 |
|
|
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis |
| Everest Medicines (1952.HK) announced the commercial launch of VELSIPITY(R) (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First Affiliated Hospital of Sun Yat-sen University, marking a milestone in patient access in the region. According to reports, on the day the first prescription was issued in mainland China, VELSIPITY(R) was simultaneously prescribed in eight tertiary hospitals across seven key cities'Guangzhou, Shanghai, Hangzhou, Xi'an, Chongqing, Beijing, and Nanjing'achieving immediate coverage of patients in major regions nationwide on its launch day. more info >> |
|
|
云顶新耀维适平(R)中国大陆首张处方落地 填补中重度溃疡性结肠炎治疗空白 |
| 云顶新耀（01952.HK）宣布，旗下自身免疫性疾病领域核心产品维适平(R)（精氨酸艾曲莫德片，VELSIPITY(R)）中国大陆首张处方在3月9日于中山大学附属第一医院开出，标志着这款创新疗法正式进入中国临床应用阶段。 more info >> |
|
|
雲頂新耀維適平(R)中國大陸首張處方落地 填補中重度潰瘍性結腸炎治療空白 |
| 雲頂新耀（01952.HK）宣佈，旗下自身免疫性疾病領域核心產品維適平(R)（精氨酸艾曲莫德片，VELSIPITY(R)）中國大陸首張處方在3月9日於中山大學附屬第一醫院開出，標志著這款創新療法正式進入中國臨床應用階段。 more info >> |
|
| Wednesday, February 25, 2026 |
|
|
Everest Medicines Shareholders Pass Resolutions Including Commercialization Service Agreement at EGM |
| Everest Medicines shareholders passed all proposed resolutions at an extraordinary general meeting (the 'EGM') held virtually on February 24, 2026, the company said in a filing. more info >> |
|
|
|
|
